KVUE$17.20

Kenvue’s portfolio does not benefit from true network effects. A household buying Tylenol, Band-Aid, or Listerine does not make the product more valuable for the next buyer in the way a software platform or marketplace does. Even where brand awareness spreads through word of mouth, that is not a reinforcing network that compounds with each incremental user. Retail shelf presence, pharmacist recommendation, and online reviews matter, but they are weak substitutes for a real network. Consumers also multi-home across branded and store-brand products without much friction, so usage at one channel or family does not lock in others. The value proposition stays product-specific, not user-ecosystem-based.

Switching costs are modest at best. Many purchases are habitual, and health-related products can feel riskier to replace than ordinary packaged goods, but that still does not create true lock-in. A shopper can move from Kenvue’s oral-care or analgesic products to a competitor’s brand or to a retailer private label with little monetary or operational disruption. Some categories have softer friction because consumers trust a familiar name after years of use, and households may remain loyal to a product that appears to work. Yet that loyalty is behavioral, not contractual or technical. Retailers also can swap shelf space quickly, so Kenvue must continually earn repurchase rather than rely on migration costs.

Intangible assets are Kenvue’s clearest strength. The company owns a long list of recognizable brands with deep consumer trust, especially Tylenol, Listerine, Band-Aid, Neutrogena, Johnson’s, and Zyrtec. In consumer health, that trust matters because buyers often associate brand names with safety, efficacy, and family use. Regulatory hurdles also create some friction around claims and formulations, which favors established players that know how to navigate approvals and category-specific rules. Still, these assets are not fully protected. Many products face generic competition, and brand equity can be damaged quickly by safety controversies or failed claims. The advantage is real and durable, but it remains execution-dependent rather than legally unassailable.

Kenvue has some scale-based cost benefits in manufacturing, procurement, logistics, and media spending, but the edge is not large enough to qualify as a durable structural cost moat. As a sizable global consumer health player, it can spread overhead across a broad portfolio and leverage established distribution relationships. However, peers such as Haleon, Procter & Gamble, Unilever, Kimberly-Clark, and private-label suppliers can also operate at meaningful scale. In many categories, innovation, promotion, and retailer relationships matter as much as unit cost. The company does not appear to possess a unique raw-material advantage, a singular manufacturing process, or a cost position that rivals cannot reasonably match over time. Scale helps margins, but it is not decisive.

Kenvue operates in categories that are too broad and too competitive to support an efficient-scale moat. Consumer health is not a natural monopoly, and barriers to entry are limited compared with infrastructure, utilities, or regulated distribution networks. Several large global companies compete across adjacent segments, while store brands and generics keep pricing discipline tight. Certain niches may have a few strong incumbents, but the overall market remains sufficiently contestable that new or smaller players can still gain share with the right brand positioning or retail support. Kenvue’s scale helps it participate efficiently, yet the market structure does not protect it from ongoing rivalry. The industry looks like oligopoly-plus-fragmentation, not a protected club.